Northland Capmk Has Negative Estimate for BLFS Q4 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Northland Capmk cut their Q4 2024 earnings per share estimates for BioLife Solutions in a report issued on Wednesday, January 8th. Northland Capmk analyst C. Byrnes now forecasts that the medical equipment provider will post earnings of ($0.04) per share for the quarter, down from their prior forecast of ($0.01). The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.05) EPS.

Other equities research analysts have also recently issued research reports about the company. Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday, January 8th. Craig Hallum lifted their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. HC Wainwright reduced their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. KeyCorp raised their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Finally, Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $26.27 on Monday. BioLife Solutions has a twelve month low of $14.50 and a twelve month high of $28.88. The company has a market capitalization of $1.22 billion, a P/E ratio of -24.78 and a beta of 1.92. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a 50-day moving average price of $26.07 and a two-hundred day moving average price of $24.42.

Institutional Trading of BioLife Solutions

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Mark Sheptoff Financial Planning LLC acquired a new stake in BioLife Solutions in the third quarter worth approximately $28,000. Quest Partners LLC bought a new stake in BioLife Solutions during the third quarter worth approximately $57,000. GAMMA Investing LLC increased its holdings in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of BioLife Solutions during the 2nd quarter valued at $122,000. Finally, Arizona State Retirement System bought a new stake in shares of BioLife Solutions during the 2nd quarter worth $217,000. 93.24% of the stock is currently owned by institutional investors.

Insider Transactions at BioLife Solutions

In related news, EVP Aby J. Mathew sold 17,604 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $20.05, for a total value of $352,960.20. Following the sale, the executive vice president now owns 284,442 shares of the company’s stock, valued at approximately $5,703,062.10. This trade represents a 5.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Greef Roderick De sold 46,896 shares of the business’s stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $23.43, for a total value of $1,098,773.28. Following the transaction, the chief executive officer now owns 414,958 shares of the company’s stock, valued at approximately $9,722,465.94. This represents a 10.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,129 shares of company stock worth $2,344,018. 2.20% of the stock is currently owned by corporate insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.